Therefore, our newly characterized Bard1‐deficient, orthotopic metastasis model can be used to accelerate the evaluation of PARP inhibitor efficacy in metastatic breast cancers harboring sensitizing BRCA1/2 pathway mutations. The gene discussed is BARD1; the disease is breast carcinoma.